CA3226849A1 - Ulodesine salt - Google Patents

Ulodesine salt Download PDF

Info

Publication number
CA3226849A1
CA3226849A1 CA3226849A CA3226849A CA3226849A1 CA 3226849 A1 CA3226849 A1 CA 3226849A1 CA 3226849 A CA3226849 A CA 3226849A CA 3226849 A CA3226849 A CA 3226849A CA 3226849 A1 CA3226849 A1 CA 3226849A1
Authority
CA
Canada
Prior art keywords
ulodesine
hemi
glutarate
salt
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3226849A
Other languages
English (en)
French (fr)
Inventor
Yao HAN
Xianfeng CHAI
Juan Liu
Qiuhong LUO
Thomas MEHRLING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laevoroc Immunology Ag
Original Assignee
Laevoroc Immunology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laevoroc Immunology Ag filed Critical Laevoroc Immunology Ag
Publication of CA3226849A1 publication Critical patent/CA3226849A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/12—Glutaric acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3226849A 2021-07-20 2022-07-20 Ulodesine salt Pending CA3226849A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2110403.9A GB202110403D0 (en) 2021-07-20 2021-07-20 Ulodesine Salt
GB2110403.9 2021-07-20
PCT/EP2022/070369 WO2023001893A1 (en) 2021-07-20 2022-07-20 Ulodesine salt

Publications (1)

Publication Number Publication Date
CA3226849A1 true CA3226849A1 (en) 2023-01-26

Family

ID=77443478

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3226849A Pending CA3226849A1 (en) 2021-07-20 2022-07-20 Ulodesine salt

Country Status (9)

Country Link
EP (1) EP4373579A1 (https=)
JP (1) JP2024525254A (https=)
KR (1) KR20240038017A (https=)
CN (1) CN117897383A (https=)
AU (1) AU2022314207A1 (https=)
CA (1) CA3226849A1 (https=)
GB (1) GB202110403D0 (https=)
MX (1) MX2024000936A (https=)
WO (1) WO2023001893A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202218782D0 (en) 2022-12-13 2023-01-25 Mehrling Thomas Purine nucleoside phosphorylase inhibitor for metabolic syndrome
WO2025250900A1 (en) * 2024-05-30 2025-12-04 Caamtech, Inc. 4-hydroxy-n,n-diisopropyltryptaminium hydroglutarate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539783B1 (en) 2002-08-21 2011-04-13 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside phosphorylases and nucleosidases
NZ595590A (en) * 2009-03-24 2013-11-29 Biocryst Pharm Inc Useful pharmaceutical salts of 7-[(3r,4r)-3-hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one

Also Published As

Publication number Publication date
CN117897383A (zh) 2024-04-16
EP4373579A1 (en) 2024-05-29
JP2024525254A (ja) 2024-07-11
KR20240038017A (ko) 2024-03-22
AU2022314207A1 (en) 2024-01-18
GB202110403D0 (en) 2021-09-01
WO2023001893A4 (en) 2023-03-30
WO2023001893A1 (en) 2023-01-26
MX2024000936A (es) 2024-06-19

Similar Documents

Publication Publication Date Title
AU2018234814B2 (en) Crystal forms of amino lipids
US8501753B2 (en) Useful pharmaceutical salts of 7-[(3R, 4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3, 5-dihydro-pyrrolo [3, 2-D] pyrimidin-4-one
ES2530258T3 (es) Síntesis de una forma cristalina de sal tartrato de N-(4-fluorobencil)-N-(1-metilpiperidin-4-il)-N'-(4-(2-metilpropiloxi)fenilmetil)carbamida
AU2003212500B2 (en) Novel crystalline forms of the anti-cancer compound ZD1839
US20180002338A1 (en) Short-acting benzodiazepine salts and their polymorphic forms
KR20180030964A (ko) 이브루티닙과 카복실산의 공결정체
KR20140075703A (ko) 프리도피딘 하이드로클로라이드의 다형 형태
AU2013333953A1 (en) Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
CA3226849A1 (en) Ulodesine salt
CN113840604A (zh) Jak2抑制剂的结晶形式
Skořepová et al. Increasing dissolution of trospium chloride by co-crystallization with urea
CN114072406B (zh) Flna-结合化合物及其盐酸盐的固体多晶型物
US12202834B2 (en) Solid state forms of oclacitinib maleate
JP2020532510A (ja) 化合物の塩及びその結晶形態
AU2021294796B2 (en) Salt of compound and pharmaceutical composition containing salt
WO2018119291A1 (en) Synthetic methods
KR20220087461A (ko) Gabaa 포지티브 알로스테릭 조정제 화합물, 그의 제조 방법 및 용도
US20240217961A1 (en) (S)-Mepazine Salt Forms, Process of Preparing, and Formulations Thereof
KR20170036288A (ko) 시타글립틴의 신규염 및 이의 제조방법
CN107868059B (zh) 一种喹唑啉衍生物的盐、其制备方法及应用
US20230105181A1 (en) Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine
TW202600556A (zh) Ｋｉｆ１８ａ抑制劑的可藥用鹽、晶型及其製備方法和用途
HK40062038B (zh) 呋喃并咪唑并吡啶类化合物的合成方法、多晶型物、及盐的多晶型物
CN116178277A (zh) 氯比普兰甲磺酸盐晶型及其制备方法
CN114040908A (zh) 一种凝血因子XIa抑制剂的晶型及其制备方法

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240715

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241218

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241218

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250625

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250625